SCHEMBL10158905

SCHEMBL10158905

CC[C@@]1(CO)O[C@@H]2OC(C)(C)OC2[C@H]1OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
GSTP1 P09211 2/20 0.33
IDO1 P14902 1/20 0.33
SIGMAR1 Q99720 1/20 0.32
GLB1 P16278 1/20 0.32
BCHE P06276 1/20 0.31
CYP3A4 P08684 2/20 0.31
MAPK1 P28482 2/20 0.31
TSHR P16473 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
PDPK1 O15530 1/20 0.31
MTOR P42345 1/20 0.31
OPRM1 P35372 1/20 0.30
OPRL1 P41146 1/20 0.30
CHRNB2 P17787 1/20 0.30
CHRNB4 P30926 1/20 0.30
CHRNA3 P32297 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11981103 1.00 ALDH1A1 (0.36) ALDH1A1MEN1KMT2AGSTP1IDO1
SCHEMBL10158790 1.00 ALDH1A1 (0.36) ALDH1A1MEN1KMT2AGSTP1IDO1
SCHEMBL25967805 1.00 ALDH1A1 (0.36) ALDH1A1MEN1KMT2AGSTP1IDO1
SCHEMBL18568726 0.94 ALDH1A1 (0.38) ALDH1A1MEN1KMT2AGSTP1IDO1
SCHEMBL14929223 0.94 ALDH1A1 (0.38) ALDH1A1MEN1KMT2AGSTP1IDO1
SCHEMBL24371821 0.94 ALDH1A1 (0.38) ALDH1A1MEN1KMT2AGSTP1IDO1
SCHEMBL10158814 0.94 ALDH1A1 (0.38) ALDH1A1MEN1KMT2AGSTP1IDO1
SCHEMBL1096325 0.94 ALDH1A1 (0.38) ALDH1A1MEN1KMT2AGSTP1IDO1
SCHEMBL2308101 0.94 ALDH1A1 (0.38) ALDH1A1MEN1KMT2AGSTP1IDO1
SCHEMBL7865382 0.94 ALDH1A1 (0.38) ALDH1A1MEN1KMT2AGSTP1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9127280-B2 Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredient OSAKA UNIVERSITY (JP) 2015-09-08 US disclosed
US-8927513-B2 5′ phosphate mimics ALNYLAM PHARMACEUTICALS, INC. (US) 2015-01-06 US disclosed
US-20130172402-A1 OLIGONUCLEOTIDE, AND THERAPEUTIC AGENT FOR DYSLIPIDEMIA CONTAINING OLIGONUCLEOTIDE AS ACTIVE INGREDIENT OSAKA UNIVERSITY (JP) 2013-07-04 US disclosed
US-20120157511-A1 5' PHOSPHATE MIMICS ALNYLAM PHARMACEUTICALS, INC. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157511-A1 5' PHOSPHATE MIMICS NSUN2, RNGTT, RNMT ALDH1A1 3422/4885MEN1 3138/4885KMT2A 3123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.